Lifastuzumab vedotin
Lifastuzumab vedotin
Lifastuzumab vedotin (pronunciation: li-fas-TUZ-oo-mab ve-DOE-tin) is a monoclonal antibody-drug conjugate designed to treat various types of cancer.
Etymology
The name "Lifastuzumab vedotin" is derived from the following components: "li" for immunoglobulin (Ig) light chain, "fa" for fascin, the intended antigen target, "stuzu" for stuzumab, a stem used for humanized antibodies, and "mab" for monoclonal antibody. "Vedotin" refers to the cytotoxic drug that is attached to the antibody.
Mechanism of Action
Lifastuzumab vedotin works by binding to the fascin protein, which is overexpressed in many types of cancer cells. Once bound, the drug is internalized by the cancer cell, where the cytotoxic drug vedotin is released, leading to cell death.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Fascin: A protein that is often overexpressed in cancer cells and is the target of lifastuzumab vedotin.
- Vedotin: A cytotoxic drug that is attached to the lifastuzumab antibody to kill cancer cells.
- Immunoglobulin: A type of protein that is part of the immune system and is used in the naming of lifastuzumab vedotin.
See Also
External links
- Medical encyclopedia article on Lifastuzumab vedotin
- Wikipedia's article - Lifastuzumab vedotin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski